Relmada Therapeutics reports Q2 EPS (84c), consensus (90c)

As of June 30 the Company had cash, cash equivalents, and short-term investments of approximately $118.5M, compared to cash, cash equivalents, and short-term investments of approximately $148.3M at December 31, 2022. “We continue to execute on the Phase 3 clinical development plan for REL-1017 as an adjunctive treatment for major depressive disorder (MDD),” said Sergio Traversa, Relmada’s CEO. “Enrollment in the ongoing Reliance II is progressing as expected, and we remain on track to complete this trial in the first half of 2024. We were also pleased to initiate Relight, our new Phase 3 Study, with screening ongoing. We currently anticipate the completion of Relight in the second half of next year. Moreover, the one year, open-label safety study, Reliance-OLS, with REL-1017 was recently completed, and we are preparing for the availability of data from that study during the current quarter.”